Leerink Partnrs Has Pessimistic View of ALNY FY2024 Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Stock analysts at Leerink Partnrs dropped their FY2024 EPS estimates for shares of Alnylam Pharmaceuticals in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst M. Foroohar now anticipates that the biopharmaceutical company will post earnings per share of ($2.48) for the year, down from their prior estimate of ($1.74). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.18) per share. Leerink Partnrs also issued estimates for Alnylam Pharmaceuticals’ Q4 2024 earnings at ($0.94) EPS, FY2025 earnings at ($2.00) EPS and FY2026 earnings at $0.49 EPS.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. The company’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.15 EPS.

Several other research analysts also recently commented on ALNY. HC Wainwright reiterated a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Piper Sandler reiterated an “overweight” rating and issued a $296.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday. Finally, William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $298.61.

Alnylam Pharmaceuticals Stock Up 3.4 %

Alnylam Pharmaceuticals stock opened at $275.54 on Thursday. The company has a market capitalization of $35.54 billion, a P/E ratio of -105.17 and a beta of 0.34. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The firm’s fifty day simple moving average is $246.27 and its 200-day simple moving average is $260.10.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds have recently modified their holdings of ALNY. Huntington National Bank lifted its holdings in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 45 shares during the period. Hollencrest Capital Management acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. R Squared Ltd acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $33,000. Washington Trust Advisors Inc. acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at approximately $42,000. Finally, True Wealth Design LLC lifted its holdings in Alnylam Pharmaceuticals by 15,300.0% in the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 153 shares during the period. 92.97% of the stock is owned by institutional investors.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,752 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00. Following the sale, the chief marketing officer now directly owns 15,705 shares of the company’s stock, valued at approximately $3,941,955. This represents a 10.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the sale, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. This represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,122 shares of company stock worth $2,540,455 over the last ninety days. Corporate insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.